iScience (Aug 2020)
Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening
- Zhichao Li,
- Youhui Qian,
- Wujiao Li,
- Lisa Liu,
- Lei Yu,
- Xia Liu,
- Guodong Wu,
- Youyu Wang,
- Weibin Luo,
- Fuyuan Fang,
- Yuchen Liu,
- Fei Song,
- Zhiming Cai,
- Wei Chen,
- Weiren Huang
Affiliations
- Zhichao Li
- Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China; International Cancer Center, Shenzhen University School of Medicine, Shenzhen, Guangdong 518060, China; Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen, Guangdong 518035, China
- Youhui Qian
- Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China
- Wujiao Li
- Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China; International Cancer Center, Shenzhen University School of Medicine, Shenzhen, Guangdong 518060, China; Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen, Guangdong 518035, China
- Lisa Liu
- Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China; International Cancer Center, Shenzhen University School of Medicine, Shenzhen, Guangdong 518060, China; Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen, Guangdong 518035, China
- Lei Yu
- Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China; International Cancer Center, Shenzhen University School of Medicine, Shenzhen, Guangdong 518060, China; Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen, Guangdong 518035, China
- Xia Liu
- Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China
- Guodong Wu
- Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China
- Youyu Wang
- Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China
- Weibin Luo
- Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China
- Fuyuan Fang
- Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China
- Yuchen Liu
- Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China; International Cancer Center, Shenzhen University School of Medicine, Shenzhen, Guangdong 518060, China; Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen, Guangdong 518035, China
- Fei Song
- Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China; International Cancer Center, Shenzhen University School of Medicine, Shenzhen, Guangdong 518060, China; Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen, Guangdong 518035, China
- Zhiming Cai
- Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China; Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong 518055, China; International Cancer Center, Shenzhen University School of Medicine, Shenzhen, Guangdong 518060, China; The First Affiliated Hospital of Shantou University, Shantou, Guangdong 515041, China; Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen, Guangdong 518035, China
- Wei Chen
- Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China; International Cancer Center, Shenzhen University School of Medicine, Shenzhen, Guangdong 518060, China; The First Affiliated Hospital of Shantou University, Shantou, Guangdong 515041, China; Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen, Guangdong 518035, China; Corresponding author
- Weiren Huang
- Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China; Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong 518055, China; International Cancer Center, Shenzhen University School of Medicine, Shenzhen, Guangdong 518060, China; The First Affiliated Hospital of Shantou University, Shantou, Guangdong 515041, China; Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen, Guangdong 518035, China; Corresponding author
- Journal volume & issue
-
Vol. 23,
no. 8
p. 101411
Abstract
Summary: Lung cancer is an extremely heterogeneous disease, and its treatment remains one of the most challenging tasks in medicine. Few existing laboratory lung cancer models can faithfully recapitulate the diversity of the disease and predict therapy response. Here, we establish 12 patient-derived organoids from the most common lung cancer subtype, lung adenocarcinoma (LADC). Extensive gene and histopathology profiling show that the tumor organoids retain the histological architectures, genomic landscapes, and gene expression profiles of their parental tumors. Patient-derived lung cancer organoids are amenable for biomarker identification and high-throughput drug screening in vitro. This study should enable the generation of patient-derived lung cancer organoid lines, which can be used to further the understanding of lung cancer pathophysiology and to assess drug response in personalized medicine.
